These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

252 related articles for article (PubMed ID: 17911598)

  • 1. Cross-regulation between type I and type II NKT cells in regulating tumor immunity: a new immunoregulatory axis.
    Ambrosino E; Terabe M; Halder RC; Peng J; Takaku S; Miyake S; Yamamura T; Kumar V; Berzofsky JA
    J Immunol; 2007 Oct; 179(8):5126-36. PubMed ID: 17911598
    [TBL] [Abstract][Full Text] [Related]  

  • 2. NKT cells in immunoregulation of tumor immunity: a new immunoregulatory axis.
    Terabe M; Berzofsky JA
    Trends Immunol; 2007 Nov; 28(11):491-6. PubMed ID: 17964217
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A novel immunoregulatory axis of NKT cell subsets regulating tumor immunity.
    Berzofsky JA; Terabe M
    Cancer Immunol Immunother; 2008 Nov; 57(11):1679-83. PubMed ID: 18369622
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A nonclassical non-Valpha14Jalpha18 CD1d-restricted (type II) NKT cell is sufficient for down-regulation of tumor immunosurveillance.
    Terabe M; Swann J; Ambrosino E; Sinha P; Takaku S; Hayakawa Y; Godfrey DI; Ostrand-Rosenberg S; Smyth MJ; Berzofsky JA
    J Exp Med; 2005 Dec; 202(12):1627-33. PubMed ID: 16365146
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Differential regulation of cytokine production by CD1d-restricted NKT cells in response to superantigen staphylococcal enterotoxin B exposure.
    Ragin MJ; Sahu N; August A
    Infect Immun; 2006 Jan; 74(1):282-8. PubMed ID: 16368982
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Up-regulation of CD1d expression restores the immunoregulatory function of NKT cells and prevents autoimmune diabetes in nonobese diabetic mice.
    Falcone M; Facciotti F; Ghidoli N; Monti P; Olivieri S; Zaccagnino L; Bonifacio E; Casorati G; Sanvito F; Sarvetnick N
    J Immunol; 2004 May; 172(10):5908-16. PubMed ID: 15128771
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A subset of NKT cells that lacks the NK1.1 marker, expresses CD1d molecules, and autopresents the alpha-galactosylceramide antigen.
    Hameg A; Apostolou I; Leite-De-Moraes M; Gombert JM; Garcia C; Koezuka Y; Bach JF; Herbelin A
    J Immunol; 2000 Nov; 165(9):4917-26. PubMed ID: 11046017
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Tissue-specific segregation of CD1d-dependent and CD1d-independent NK T cells.
    Eberl G; Lees R; Smiley ST; Taniguchi M; Grusby MJ; MacDonald HR
    J Immunol; 1999 Jun; 162(11):6410-9. PubMed ID: 10352254
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Tissue-Specific Roles of NKT Cells in Tumor Immunity.
    Terabe M; Berzofsky JA
    Front Immunol; 2018; 9():1838. PubMed ID: 30158927
    [TBL] [Abstract][Full Text] [Related]  

  • 10. NKT cells in tumor immunity: opposing subsets define a new immunoregulatory axis.
    Berzofsky JA; Terabe M
    J Immunol; 2008 Mar; 180(6):3627-35. PubMed ID: 18322166
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Type I NKT cells protect (and type II NKT cells suppress) the host's innate antitumor immune response to a B-cell lymphoma.
    Renukaradhya GJ; Khan MA; Vieira M; Du W; Gervay-Hague J; Brutkiewicz RR
    Blood; 2008 Jun; 111(12):5637-45. PubMed ID: 18417738
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Dissociation of NKT stimulation, cytokine induction, and NK activation in vivo by the use of distinct TCR-binding ceramides.
    Ortaldo JR; Young HA; Winkler-Pickett RT; Bere EW; Murphy WJ; Wiltrout RH
    J Immunol; 2004 Jan; 172(2):943-53. PubMed ID: 14707067
    [TBL] [Abstract][Full Text] [Related]  

  • 13. CD1d-restricted natural killer T cells can down-regulate tumor immunosurveillance independent of interleukin-4 receptor-signal transducer and activator of transcription 6 or transforming growth factor-beta.
    Terabe M; Khanna C; Bose S; Melchionda F; Mendoza A; Mackall CL; Helman LJ; Berzofsky JA
    Cancer Res; 2006 Apr; 66(7):3869-75. PubMed ID: 16585215
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Adenosine A2A receptor activation reduces hepatic ischemia reperfusion injury by inhibiting CD1d-dependent NKT cell activation.
    Lappas CM; Day YJ; Marshall MA; Engelhard VH; Linden J
    J Exp Med; 2006 Nov; 203(12):2639-48. PubMed ID: 17088433
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Involvement of secretory and endosomal compartments in presentation of an exogenous self-glycolipid to type II NKT cells.
    Roy KC; Maricic I; Khurana A; Smith TR; Halder RC; Kumar V
    J Immunol; 2008 Mar; 180(5):2942-50. PubMed ID: 18292516
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Human invariant V alpha 24-J alpha Q TCR supports the development of CD1d-dependent NK1.1+ and NK1.1- T cells in transgenic mice.
    Capone M; Cantarella D; Schümann J; Naidenko OV; Garavaglia C; Beermann F; Kronenberg M; Dellabona P; MacDonald HR; Casorati G
    J Immunol; 2003 Mar; 170(5):2390-8. PubMed ID: 12594262
    [TBL] [Abstract][Full Text] [Related]  

  • 17. In vivo antitumor activity of NKT cells activated by the combination of IL-12 and IL-18.
    Baxevanis CN; Gritzapis AD; Papamichail M
    J Immunol; 2003 Sep; 171(6):2953-9. PubMed ID: 12960319
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Donor bone marrow type II (non-Valpha14Jalpha18 CD1d-restricted) NKT cells suppress graft-versus-host disease by producing IFN-gamma and IL-4.
    Kim JH; Choi EY; Chung DH
    J Immunol; 2007 Nov; 179(10):6579-87. PubMed ID: 17982047
    [TBL] [Abstract][Full Text] [Related]  

  • 19. NKT cells in the rat: organ-specific distribution of NK T cells expressing distinct V alpha 14 chains.
    Matsuura A; Kinebuchi M; Chen HZ; Katabami S; Shimizu T; Hashimoto Y; Kikuchi K; Sato N
    J Immunol; 2000 Mar; 164(6):3140-8. PubMed ID: 10706704
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Direct regulatory role of NKT cells in allogeneic graft survival is dependent on the quantitative strength of antigenicity.
    Oh K; Kim S; Park SH; Gu H; Roopenian D; Chung DH; Kim YS; Lee DS
    J Immunol; 2005 Feb; 174(4):2030-6. PubMed ID: 15699132
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.